Theravance Biopharma (TBPHV) versus Its Peers Financial Comparison
Theravance Biopharma (NASDAQ: TBPHV) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Theravance Biopharma to related businesses based on the strength of its valuation, risk, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Earnings and Valuation
This table compares Theravance Biopharma and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Theravance Biopharma Competitors||$8.39 billion||$1.12 billion||51.26|
Theravance Biopharma’s competitors have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Theravance Biopharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Theravance Biopharma Competitors||-2,902.57%||-69.29%||-9.41%|
This is a breakdown of recent ratings for Theravance Biopharma and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Theravance Biopharma Competitors||843||3746||6738||184||2.54|
As a group, “Pharmaceuticals” companies have a potential upside of 35.65%. Given Theravance Biopharma’s competitors higher possible upside, analysts clearly believe Theravance Biopharma has less favorable growth aspects than its competitors.
Institutional & Insider Ownership
43.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.9% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Theravance Biopharma has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Theravance Biopharma’s competitors have a beta of 0.99, suggesting that their average share price is 1% less volatile than the S&P 500.
Theravance Biopharma competitors beat Theravance Biopharma on 6 of the 8 factors compared.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.